检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:邱芸[1] QIU Yun(Department of Anesthesiology,Suzhou Yongding Hospital,Suzhou 215200,China)
出 处:《中国医药指南》2020年第15期48-49,共2页Guide of China Medicine
摘 要:目的探索右美托咪定联合芬太尼辅助局麻用药布比卡因和利多卡因应用于外周神经阻滞麻醉的临床效果。方法66例行外周神经阻滞麻醉患者随机分为对照组和试验组,每组33例。对照组患者给予30 mL的0.25%布比卡因和0.67%利多卡因混合液后经静脉注射1.5μg/kg芬太尼;试验组患者在对照组患者麻醉方案基础上加静脉泵注右美托咪定。结果对照组和试验组患者临床资料无显著差异(P>0.05),结果具有可比性。和术前相比,对照组患者术中的平均动脉压(MAP)和心率(HR)明显上升,血氧饱和度(SpO2),差异均具有统计学意义(P<0.05);试验组患者则无明显差异(P>0.05)。对照组87.8%的患者镇静效果为Ramsay 1~2级,而试验组93.9%的患者为Ramsay 4~5级的水平。结论右美托咪定联合芬太尼辅助局麻用药布比卡因和利多卡因应用于外周神经阻滞,患者生命体征平稳,镇静效果良好,麻醉效果确切,保证了患者的舒适度和手术的安全性。Objective To investigate the clinic benefits of combining Dexmedetomidine and Fentanyl as adjuvants in peripheral nerve blocks.Method A total of 66 patients were allocated randomly into two groups,a control group and a test group.Patients in the control group were administered with 30 mL of bupivacaine(0.25%)and lidocaine(0.67%),followed by Fentanyl at 1.5μg/kg.Patients in the test group were administered additionally with dexmedetomidine(IV)at the same basic regimen with the control group.Results There were no clear differences observed between two groups in clinical parameters.When compared to pre-operation,the MAP and HR in the control group were increased statistically(P<0.05),and SpO2 was deceased statistically(P<0.05)during operation.When compared to pre-operation,there was not observed of any difference for the MAP,HR and SpO2 during operation.About 87.8%patients in the control group was classed as the sedation scale of level 1-2,and about 93.9%patients in the test group was classed as the sedation scale of level 4-5.Conclusion Combination of dexmedetomidine and fentanyl could be the optimized anaesthesiaadjuvant to be used in the peripheralnerve blocks with expected and satisfying clinical effect.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.3